Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Clifford A. Hudis, MD, Allen S. Lichter, MD, and Richard L. Schilsky, MD, on Passing the Torch

Richard L. Schilsky, MD (right), Chief Medical Officer of ASCO, talks with incoming ASCO CEO Clifford A. Hudis, MD (left) and outgoing CEO Allen S. Lichter, MD (center) about the passing of the torch and their perspectives on past accomplishments and future goals of the society.

Colorectal Cancer

Heinz-Josef Lenz, MD, and Marc Ychou, MD, on Treating mCRC With Initially Nonresectable Liver Metastases

Heinz-Josef Lenz, MD, of the University of Southern California, and Marc Ychou, MD, of the Centre Régional de Lutte Contre Le Cancer, discuss study findings on FOLFIRINOX combined with targeted therapy according to RAS status for colorectal cancer patients with initially nonresectable liver metastases (Abstract 3512).

Issues in Oncology

Eric Roeland, MD, and Timothy E. Quill, MD, on the Debate Over Physician-Assisted Death

Eric Roeland, MD, of the University of California, San Diego, and Timothy E. Quill, MD, of the University of Rochester Medical Center, discuss the debate on whether physician-assisted death should be a legally available option at the end of life when neither palliative nor hospice care is satisfactory.

Multiple Myeloma

Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial (Italian Language Version)

Antonio Palumbo, MD, of the University of Torino, discusses in Italian this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract LBA4).

To see the English language version of this video, please click here.

Lung Cancer

Vali A. Papadimitrakopoulou, MD, and Gideon Michael Blumenthal, MD, on NSCLC: An Updated Pooled Analysis

Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Gideon Michael Blumenthal, MD, of the US Food and Drug Administration, discuss milestone analyses with immune checkpoint inhibitors, targeted therapy, and standard therapy in metastatic non–small cell lung cancer trials submitted to the FDA (Abstract 9010).

Jul

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Clifford A. Hudis, MD, Allen S. Lichter, MD, and Richard L. Schilsky, MD, on Passing the Torch

Heinz-Josef Lenz, MD, and Marc Ychou, MD, on Treating mCRC With Initially Nonresectable Liver Metastases

Eric Roeland, MD, and Timothy E. Quill, MD, on the Debate Over Physician-Assisted Death

Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial (Italian Language Version)

Vali A. Papadimitrakopoulou, MD, and Gideon Michael Blumenthal, MD, on NSCLC: An Updated Pooled Analysis

Breast Cancer: Tailoring Radiotherapy Based on Nodal Response to Primary Chemotherapy

Novel Gene Therapy–Radiotherapy Combination in Localized Prostate Cancer

Advanced Breast Cancer Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor

Emergency Hospital Admission Accounts for 40 of Ovarian Cancer Diagnoses in England

Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal-Only Metastases